Stay Informed: Transforming Radiology with Structured Reporting and Data-Driven Approaches

Dive into our activities, projects, and product updates. Catch on the latest industry news and learn who we are as a company and as a team.

Hands holding a glass lung

Comparison of iRECIST and RECIST 1.1 for Evaluating Immunotherapy in Melanoma and Non-Small Cell Lung Cancer

In a retrospective study conducted at the University Hospital Cologne, the radiological criteria iRECIST and RECIST 1.1 were compared for assessing treatment response in melanoma and NSCLC patients receiving immune checkpoint inhibitors.

The results indicate that iRECIST is better suited for capturing atypical treatment responses to immunotherapies, especially in patients experiencing pseudoprogression. iRECIST could thus contribute to a more accurate evaluation of treatment response and improved immunotherapy outcomes.

Read more about the study here.

Clinical Research Standardized Reading Procedures iRECIST RECIST Research with mint mintLesion

Related Resources

Related Resources

A picture of a person looking at a brain scan and the interface of mint Lesion™ on a computer

Advancing Neuro-Oncology Assessments: Mint Medical to Integrate Newly Published RANO 2.0 Criteria into mint Lesion™

Glioblastomas and other gliomas are the most common malignant primary brain tumor types, yet few effective therapies are available. Clinical research…

A picture of radiologists looking at a screen showing the restaging of the HNSCC

Study Highlights the Potential of Radiomics in Medical Intervention

A recent study conducted by the Medical University of Innsbruck highlights the potential of radiomics in exploring the impacts of Radiochemotherapy…

Medical University of Innsbruck: Radiomic Assessment of Radiation-Induced Alterations of Skeletal Muscle Composition in Head and Neck Squamous Cell Carcinoma within the Currently Clinically Defined Optimal Time Window for Salvage Surgery

This study [1] aimed to examine tissue changes in patients with head and neck squamous cell carcinoma (HNSCC) after primary radiochemotherapy (RCT)…